Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a commercial messenger RNA medicines company ...
Arcturus Therapeutics (ARCT) announced the appointment of Moncef Slaoui as chair designate. Slaoui has been serving on the company’s board of ...
Arcturus Therapeutics Holdings Inc. stock is down 46% since Sept. 2023 coverage; mRNA sector faces headwinds with public ...
Oil and gas companies Arcturus Corp. and Aschere Energy LLC, along with founder Leon Ali Parvizian, must pay more than $10 ...
In a report released today, Ed Arce from H.C. Wainwright maintained a Buy rating on Arcturus Therapeutics (ARCT – Research Report), with a ...
In the assessment of 12-month price targets, analysts unveil insights for Arcturus Therapeutics, presenting an average target ...
The co-development and project finance agreement will accelerate deployment of Skyven's cutting-edge, "decarbonizing" ...
Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a commercial messenger RNA medicines company ...
BTIG initiated coverage of Arcturus Therapeutics (ARCT) with a Buy rating and $41 price target Arcturus is a commercial-stage biotechnology ...
Equities research analysts at Leerink Partnrs upped their FY2024 EPS estimates for shares of Arcturus Therapeutics in a note ...
BTIG Research began coverage on shares of Arcturus Therapeutics (NASDAQ:ARCT – Get Free Report) in a research report issued on Tuesday, MarketBeat reports. The brokerage set a “buy” rating and a ...
Holdings Inc. (NASDAQ: ARCT), a company specializing in mRNA medicines for infectious diseases and rare disorders, has appointed Dr. Moncef Slaoui as its Chair Designate. Dr. Slaoui, a notable figure ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback